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Utility of Non-Invasive Testing for Fibrosis Assessment
in Patients with End Stage Renal Disease
Nikita Chadha, DO; Taseen Syed MBBS, MD; Richard K. Sterling, MD, MSc
Virginia Commonwealth University, Richmond, Virginia

BACKGROUND

RESULTS

Non-alcoholic fatty liver disease (NAFLD) risk factors (below) have an
increased prevalence in end stage renal disease (ESRD).

Obesity
(BMI ≥ 30)

Diabetes
Mellitus (DM)

Hypertension
(HTN)

Dyslipidemia
(DL)

May patients with ESRD have normal liver enzymes and therefore do not
have further testing to evaluate for NAFLD. Therefore, the prevalence and
severity of NAFLD in ESRD is unknown.
The goal of study was to assess utility of non-invasive testing (NIT) including
transient elastography (TE) for liver stiffness (LS), controlled attenuated
parameter (CAP) for steatosis, Fibrosis-4 (FIB-4), AST to platelet ratio (APRI)
and NAFLD Fibrosis score (NFS) (Table 1) for assessment of NAFLD in
patients with ESRD undergoing renal transplant (RT) evaluation.

METHODS
Retrospective analysis with the demographic, clinical, and laboratory data was
collected within 12 weeks of TE.
Primary outcomes evaluated for advanced fibrosis (AF, ≥F3) (defined as TE ≥ 9
kPa) and steatosis (defined as CAP ≥ 263 dB/m).
Univariate and multivariate analysis was performed to identify factors
associated with AF and steatosis.

DISCUSSION

- Comorbidities of metabolic syndrome were common with HTN being the
most prevalent followed by DM and DL (Table 2).
- AF and steatosis were observed in 21% and 25%, respectively (Table 3).
- Patients with steatosis were found to have higher BMI (p < 0.0001) and
obesity (p < 0.001).
- NFS showed reasonable accuracy to detect AF, however, did not
correlate with TE in identifying fibrosis.

Non-invasive tests

Formula

APRI

[(AST/normal AST)/platelet count (103/mL)] x 100

FIB-4

[age(years) x AST)/(platelet count (103/mL)) x Ö ALT]

NFS

-1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) +
1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 ×
AST/ALT ratio – 0.013 × platelet (×109/L) – 0.66 ×
albumin (g/dL)

-

Despite normal liver enzymes, AF and steatosis were common.

-

NFS identified fibrosis more so than APRI and FIB-4 as it includes
components of metabolic syndrome in it’s formula.

-

It is of utmost importance to identify those patients with advanced fibrosis
in ESRD as this may help gauge risk of hepatic decompensation post renal
transplantation.

-

TE and NFS showed good NPV but only moderate ability to predict
advanced fibrosis à optimal to detect patients who lack significant
fibrosis.

-

Long-term follow-up following RT in this population are needed to
determine the clinical significance of our findings.

Table 2. Demographic and median clinical values of study population
Characteristic

Characteristic

Age

Patient cohort
(n=171)
56 years

Diabetes

Patient cohort
(n=171)
47%

Male

65%

Hypertension

96%

Black

60%

Dyslipidemia

56%

Non-Hispanic

99%

AST (IU/L)

31

BMI

28.9

ALT (IU/L)

29

BMI ≥ 30

36%

Platelets x
103/mL

215

Table 3. Assessment of each non-invasive test to identify
advanced fibrosis and steatosis (%, mean (SD), Median (IQR))
Non-invasive tests

In those with available liver histology, utility of LS, FIB-4 and NFS to predict AF
was assessed.

Table 1. Formulas for Selected Non-Invasive Tests

Summary and Conclusions:
- Features of the metabolic syndrome in those presenting for RT evaluation
are common.

Transient
Elastography (TE)

AST Platelet Ratio
Index (APRI)
Fibrosis-4 Score (FIB4)
Non-alcoholic fatty
liver disease fibrosis
score (NFS)

Established cut
offs
LS kPa
LS IQR/med
LS ≥ 9
CAP dB/m
CAP IQR
CAP ≥ 263 dB/m
Probe (M/XL)
APRI
APRI > 1.5
FIB-4
FIB-4 > 2.67
NFS
NFS > 0.65

Results
8.3 (7.1), 6.5 (4.7-8.9)
13.2 (5.4)
21%
232 (61)
40 (20)
25%
62%/38%
0.35 (0.39), 0.025
(0.016-0.37)
1.8%
1.97 (1.33), 0.72 (1.072.37)
15%
-0.408 (1.61), -0.385 (1.56-0.51)
23%

Limitations:
Non-invasive tests may under represent of fibrosis as certain serological
markers such as AST and ALT may not be elevated in these patients.
Timing of when to perform TE must be considered in the ESRD population
(post-HD is preferred so that volume will not interfere with results).
Future Directions:
Multi-center study to further stratify a more global consensus with regards to a
preferred modality of testing across all ethnicities.
Only 14 patients in this study had biopsies available for correlation; may
benefit from further correlation with biopsies.
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Introduction/Background
•

Non-alcoholic fatty liver disease (NAFLD) risk factors (below) have an increased prevalence in end stage
renal disease (ESRD).
– Obesity (BMI ≥ 30)
– Diabetes Mellitus (DM)
– Hypertension (HTN)
– Dyslipidemia (DL)

•
•

May patients with ESRD have normal liver enzymes and therefore do not have further testing to evaluate
for NAFLD. Therefore, the prevalence and severity of NAFLD in ESRD is unknown.
The goal of study was to assess utility of non-invasive testing (NIT) (see below; Table 1) for assessment of
NAFLD in patients with ESRD undergoing renal transplant (RT) evaluation.
– Transient elastography (TE) for liver stiffness (LS)
– Controlled attenuated parameter (CAP) for steatosis
– Fibrosis-4 (FIB-4)
– AST to platelet ratio (APRI)
– NAFLD Fibrosis score (NFS)
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Methods
•

•

Retrospective analysis with the demographic, clinical, and laboratory data was collected within 12 weeks of
TE.
Primary outcomes evaluated for advanced fibrosis (AF, ≥F3) (defined as TE ≥ 9 kPa) and steatosis (defined
as CAP ≥ 263 dB/m).
Univariate and multivariate analysis was performed to identify factors associated with AF and steatosis.

•

In those with available liver histology, utility of LS, FIB-4 and NFS to predict AF was assessed.

•

Table 1. Formulas for Selected Non-Invasive Tests

Non-invasive tests

Formula

APRI

[(AST/normal AST)/platelet count (103/mL)] x 100

FIB-4

[age(years) x AST)/(platelet count (103/mL)) x Ö ALT]

NFS

-1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) +
1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT
ratio – 0.013 × platelet (×109/L) – 0.66 × albumin (g/dL)
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Results
•
•

Comorbidities of metabolic syndrome were common with HTN being the most prevalent followed by DM and
DL (Table 2).
AF and steatosis were observed in 21% and 25%, respectively (Table 3).

•
•

Patients with steatosis were found to have higher BMI (p < 0.0001) and obesity (p < 0.001).
NFS showed reasonable accuracy to detect AF, however, did not correlate with TE in identifying fibrosis.
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Results

Table 3. Assessment of each non-invasive test to
identify advanced fibrosis and steatosis (%, mean
(SD), Median (IQR))

Table 2. Demographic and median clinical values of
study population
Characteristic

Patient
cohort
(n=171)

Characteristic

Patient
cohort
(n=171)

Age

56 years

Diabetes

47%

Male

65%

Hypertension

96%

Black

60%

Dyslipidemia

56%

Non-Hispanic

99%

AST (IU/L)

31

BMI

28.9

ALT (IU/L)

29

BMI ≥ 30

36%

Platelets x
103/mL

215

Non-invasive
tests

Transient
Elastography
(TE)

AST Platelet
Ratio Index
(APRI)
Fibrosis-4 Score
(FIB-4)
Non-alcoholic
fatty liver disease
fibrosis score
(NFS)
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Established cut offs

Results

LS kPa

8.3 (7.1), 6.5 (4.7-8.9)

LS IQR/med

13.2 (5.4)

LS ≥ 9

21%

CAP dB/m

232 (61)

CAP IQR

40 (20)

CAP ≥ 263 dB/m

25%

Probe (M/XL)

62%/38%

APRI

0.35 (0.39), 0.025 (0.0160.37)

APRI > 1.5

1.8%

FIB-4

1.97 (1.33), 0.72 (1.072.37)

FIB-4 > 2.67

15%

NFS

-0.408 (1.61), -0.385 (1.56-0.51)

NFS > 0.65

23%
June 4, 2020
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Discussion and Conclusion
•
•
•

•

•

•

Features of the metabolic syndrome in those presenting
for RT evaluation are common.
Despite normal liver enzymes, AF and steatosis were
common.
NFS identified fibrosis more so than APRI and FIB-4 as it
includes components of metabolic syndrome in it’s
formula.
It is of utmost importance to identify those patients with
advanced fibrosis in ESRD as this may help gauge risk of
hepatic decompensation post renal transplantation.
TE and NFS showed good NPV but only moderate ability
to predict advanced fibrosis à optimal to detect
patients who lack significant fibrosis.
Long-term follow-up following RT in this population are
needed to determine the clinical significance of our
findings.

Limitations:
• Non-invasive tests may under represent of fibrosis as
certain serological markers such as AST and ALT may not
be elevated in these patients.
• Timing of when to perform TE must be considered in the
ESRD population (post-HD is preferred so that volume
will not interfere with results).
Future Directions:
Multi-center study to further stratify a more global consensus
with regards to a preferred modality of testing across all
ethnicities.
Only 14 patients in this study had biopsies available for
correlation; may benefit from further correlation with
biopsies.
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